Research

Cancer is a disease caused by the evolution of genetically diverse cell populations originating from cells acquiring advantageous genetic mutations (driver mutations), followed by the acquisition of new mutations and clonal selection, resulting in genetically heterogeneous cell populations.

In recent years, large-scale and systematic analyses of cancer genomes using next-generation sequencing (NGS) technologies have rapidly expanded our understanding of genetic mutations in various cancers. Specifically, various types of somatic abnormalities such as gene mutations, copy number alterations, structural abnormalities, and fusion genes have been identified. Moreover, insights into non-coding regions and epigenetic abnormalities have accumulated, elucidating the overall landscape of driver genetic abnormalities crucial for cancer initiation and progression.

However, many questions remain elusive regarding the biological roles of newly discovered genetic abnormalities. Additionally, much is still unknown about the molecular mechanisms by which cells harboring genetic abnormalities interact with their microenvironment and are influenced by external factors such as aging and chronic inflammation to acquire cancer-specific traits.

In our laboratory, we focus particularly on hematologic malignancies, using patient specimens and mouse models mimicking disease states. Leveraging data science techniques, including omics analyses (genome sequencing, RNA sequencing, epigenetics analysis, single-cell analysis, etc.), alongside cutting-edge molecular biology methodologies, we aim to unravel the unknown pathogenesis of cancer.

Our goal is to translate novel insights gained from basic research into clinical practice, thereby making significant contributions to the better disease management and ultimately improving public health.